bioAffinity Technologies Announces Grant of Hong Kong Patent for Company's CyPath® Lung Noninvasive Lung Cancer Diagnostic
SAN ANTONIO, September 17, 2026--bioAffinity announces new Hong Kong patent that protects the proprietary technology behind its noninvasive CyPath Lung diagnostic for lung cancer.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Yahoo